Involvement of a novel preimplantation-specific gene encoding the high mobility group box protein Hmgpi in early embryonic development by Yamada, Mitsutoshi et al.
Involvement of a novel preimplantation-speciﬁc
gene encoding the high mobility group box protein
Hmgpi in early embryonic development
Mitsutoshi Yamada1,2, Toshio Hamatani1, , Hidenori Akutsu2, Nana Chikazawa1,2, Naoaki Kuji1,
Yasunori Yoshimura1 and Akihiro Umezawa2
1Department of Obstetrics and Gynecology, Keio University School of Medicine, 35 Shinanomachi Shinjyuku-ku,
Tokyo 160-8582, Japan and
2Department of Reproductive Biology, National Research Institute for Child Health
and Development, 2-10-1 Ohkura Setagaya-ku, Tokyo 157-8535, Japan
Received August 24, 2009; Revised October 22, 2009; Accepted November 11, 2009
Mining gene-expression-proﬁling data identiﬁed a novel gene that is speciﬁcally expressed in preimplantation
embryos. Hmgpi, a putative chromosomal protein with two high-mobility-group boxes, is zygotically tran-
scribed during zygotic genome activation, but is not transcribed postimplantation. The Hmgpi-encoded
protein (HMGPI), ﬁrst detected at the 4-cell stage, remains highly expressed in pre-implantation embryos.
Interestingly, HMGPI is expressed in both the inner cell mass (ICM) and the trophectoderm, and translocated
from cytoplasm to nuclei at the blastocyst stage, indicating differential spatial requirements before and after
the blastocyst stage. siRNA (siHmgpi)-induced reduction of Hmgpi transcript levels caused developmental
loss of preimplantation embryos and implantation failures. Furthermore, reduction of Hmgpi prevented
blastocyst outgrowth leading to generation of embryonic stem cells. The siHmgpi-injected embryos also
lost ICM and trophectoderm integrity, demarcated by reduced expressions of Oct4, Nanog and Cdx2. The
ﬁndings implicated an important role for Hmgpi at the earliest stages of mammalian embryonic development.
INTRODUCTION
Preimplantation development encompasses the period from
fertilization to implantation. Oocytes cease developing at
metaphase of the second meiotic division, when transcription
stops and translation is reduced. After fertilization, sperm
chromatin is reprogrammed into a functional pronucleus and
zygotic genome activation (ZGA) begins, whereby the
maternal genetic program governed by maternally stored
RNAs and proteins must be switched to the embryonic
genetic program governed by de novo transcription (1,2).
Our previous gene expression proﬁling during preimplantation
development revealed distinctive patterns of maternal RNA
degradation and embryonic gene activation, including two
major transient ‘waves of de novo transcription’ (3). The
ﬁrst wave during the 1- to 2-cell stage corresponds to ZGA.
The second wave during the 4- to 8-cell stage, known as
mid-preimplantation gene activation (MGA), induces dramatic
morphological changes to the zygote including compaction
and blastocele formation, particularly given that few genes
show large expression changes after the 8-cell stage. ZGA
and MGA together generate a novel gene expression proﬁle
that delineates the totipotent state of each blastomere at the
cleavage stage of embryogenesis, and these steps are prerequi-
site for future cell lineage commitments and differentiation.
The ﬁrst such differentiation gives rise to the inner cell mass
(ICM), from which embryonic stem (ES) cells are derived,
as well as the trophectoderm at the blastocyst stage.
However, the molecular regulatory mechanisms underlying
this preimplantation development and ES-cell generation
from the ICM remain unclear.
Induced pluripotent stem (iPS) cells are ES cell-like pluri-
potent cells, generated by the forced expression of deﬁned
factors in somatic cells, including Pou5f1/Oct4, Sox2, Klf4
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somatic nuclei in a somewhat similar way as ooplasm does
in reconstructed oocytes by nuclear transfer (NT). However,
with the exception of Oct4, these factors are not highly
expressed maternally in oocytes, and only increased by
zygotic transcription during preimplantation, based on
expression sequence tag (EST) frequencies in Unigene
cDNA libraries and microarray data from oogenesis to preim-
plantation development (5). Although pluripotency is achieved
within 2 days in NT embryos reconstructed with a somatic
nucleus, it takes approximately 2 weeks for the establishment
of iPS cells. Such immediate induction of pluripotency during
preimplantation development is attributed to well-organized
transcriptional regulation, i.e. waves of transcription
whereby maternal gene products trigger ZGA, which in turn
fuels MGA. On the other hand, the forced simultaneous tran-
scription of iPS factors in somatic cells does not efﬁciently
induce these waves of transcription, and it takes a long time
to activate the other genes necessary for pluripotency. Study-
ing transcriptional regulation during preimplantation develop-
ment would therefore also help unravel the establishment of
iPS cells as well as pluripotency in these cells.
Large-scale EST projects (6–8) and DNA microarray
studies (3,9–11) have revealed many novel genes zygotically
expressed during preimplantation development. Very few of
these genes, however, are exclusively expressed in preimplan-
tation embryos (12), and such genes ought to have important
roles during preimplantation development. For example,
Zscan4, a novel transcription factor, is expressed speciﬁcally
in 2-cell stage embryos and a subset of ES cells (13).
Reduction of Zscan4 transcript levels by siRNAs delays pro-
gression from the 2-cell to the 4-cell stage, and produces blas-
tocysts that neither implant in vivo nor proliferate in blastocyst
outgrowth culture. Thus, a transcription factor expressed
exclusively in preimplantation embryos is potentially a key
regulator of global gene expression changes during preimplan-
tation development. On the other hand, reprogramming gene
expression during ZGA and MGA requires considerable
changes in chromatin structure (14–16), and modulation of
chromatin folding affects access of regulatory factors to
their cognate DNA-binding sites. This modulation can be
achieved by loosening the chromatin structure, by disrupting
the nucleosome structure, by DNA bending and unwinding,
and by affecting the strength of DNA-histone interactions
via postsynthetic modiﬁcations of histones (17,18). Many of
these structural changes are mediated by a large and diverse
superfamily of high-mobility-group (HMG) proteins, which
are the second most abundant chromosomal proteins after his-
tones (18).
This study identiﬁed a novel preimplantation-speciﬁc gene,
Hmgpi, which encodes a chromosomal protein containing
HMG box domains. It reports a detailed expression analysis
of Hmgpi and the Hmgpi-encoded protein (HMGPI), which
was translocated from the cytoplasm to nuclei at the blastocyst
stage. Loss-of-function studies were also conducted using
siRNA technology. The siRNA-induced reduction in Hmgpi
expression caused developmental loss at preimplantation
stages and hampered implantation through reduced prolifer-
ation of both ICM-derived cells and trophectodermal cells
during peri-implantation development.
RESULTS
Gene structure of a preimplantation-stage-speciﬁc gene,
Hmgpi
In silico analysis identiﬁed Hmgpi (an HMG-box protein,
preimplantation-embryo-speciﬁc) as a preimplantation-stage-
speciﬁc gene encoding a chromosomal protein containing
HMG box domains. The Hmgpi transcript levels are probably
upregulated during ZGA (1- to 2-cell stages) to peak at the
4-cell stage, based on gene expression proﬁling (3,9)
(Fig. 1A). Using the public expressed-sequence tag (EST)
database, 16 cDNA clones were found exclusively in
preimplantation-embryo libraries (2- to 8-cell stages)
(Fig. 1B). One of these contained the full Hmgpi gene
coding sequence (AK163257) (Fig. 1C), spanning 2579 bp
and split into two exons, which encode a protein of 394
amino acids (aa) (NP_001028965) harboring a SANT
domain (‘SWI3, ADA2, N-CoR, and TFIIIB’ DNA-binding
domain) and two HMG-box domains, based on SMART
domain prediction analysis (19) (Fig. 1C). In the NCBI
Gene database, the Hmgpi gene is called Ubtf-like 1 (Ubtﬂ1)
based on aa sequence similarity (36% identity and 58% posi-
tives by BLAST) to Ubtf-encoded protein ‘upstream binding
transcription factor’, which contains a SANT domain and six
HMG-box domains. Two rat homologs (Ubtﬂ1 and
RGD1304745) and three human homologs (UBTFL1-3)o f
the mouse Hmgpi were identiﬁed by BLASTing of
NP_001028965 against the NCBI nucleotide database. Pair-
wise alignment scores by BLAST of amino acid sequences
for rat and human homologs are 72.3–72.5% and 53.8–
54.1%, respectively (Fig. 1D and Supplementary Material,
Table S1), while those for nucleotide sequences are 83.7 and
66.8–67.0%, respectively. All these human homologs were
predicted by in silico genome-based analysis, and have no
ESTs in the Unigene database. The absence of human ESTs
may reﬂect the paucity of cDNA libraries of human preim-
plantation embryos in the Unigene database, despite speciﬁc
expression of the Hmgpi gene in human preimplantation
embryos. Based on the number and the type of HMG-box
domains, this novel protein could also be categorized into
the HMG-box family (HMGB). A dendrogram of aa sequence
similarity in HMG family proteins indicates two HMG sub-
groups (Fig. 1E). One includes the HMG-nucleosome
binding family (HMGN) and the HMG-AT-hook family
(HMGA), and the other is HMGB that includes HMGPI. All
members of HMGB contain two HMG-box domains
(‘HMG-box’ or ‘HMG-UBF_HMG-box’).
Expression of the Hmgpi gene and protein
First, we experimentally conﬁrmed the preimplantaion-stage-
speciﬁc expression pattern of Hmgpi suggested by the
in silico analysis. Northern blot analysis using a mouse mul-
tiple tissue poly(A)RNA panel (FirstChoice
w Mouse Blot 1
from Ambion, Austin, TX, USA) failed to detect expression
of the Hmgpi gene (data not shown). While RT–PCR analysis
using cDNA isolated from mouse adult tissues and fetuses (E7,
E11, E15 and E17) also failed to show Hmgpi expression,
RT–PCR analysis for preimplantation embryos indicated
Hmgpi expression from the 2-cell embryo to the blastocyst
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was detected in ES cells, although not in embryonic carcinoma
(EC) cells nor in mesenchymal stem cells (Fig. 2B). The rela-
tive abundance of Hmgpi transcripts in preimplantation
embryos was measured by real-time quantitative RT–PCR
(qRT–PCR) analysis (Fig. 2C). Four independent experiments
were conducted with four replicates of 10 embryos each. To
normalize the qRT–PCR reaction efﬁciency, H2afz was used
as an internal standard (20). Hmgpi mRNA levels increased
during the 1- to 2-cell stage, peaked at the 4-cell stage, and
then gradually decreased during the 8-cell to blastocyst
stage (Fig. 2C). The in silico-predicted preimplantation-
stage-speciﬁc expression pattern of Hmgpi was therefore
validated.
Figure 1. In silico analysis of Hmgpi expression. (A) Previous microarray analysis of Hmgpi expression. Hmgpi expression appeared at the 2-cell stage, peaked at
the 4-cell stage and then decreased (3). (B) Expression sequence tag (EST) frequencies in Unigene cDNA libraries. Out of 4.7 million mouse ESTs, 16 Hmgpi
clones were exclusively detected at the cleavage stages: 9, 2 and 5 ESTs from 2-cell, 4-cell and 8-cell libraries, respectively. (C) Exon–intron structures and a
putative protein structure of Hmgpi. Hmgpi has three exon–intron models and one protein model. Predicted protein domains are also shown. (D) Conserved
domains of Hmgpi/Ubtﬂ1 gene in mouse, rat and human. Pairwise alignment scores of conserved domains between species were shown. (E) Phylogenetic
tree of gene nucleotide acid sequences containing HMG domains determined by a sequence distance method and the neighbour-joining (NJ) algorithm (41)
using Vector NTI software (Invitrogen, Carlsbad, CA, USA).
482 Human Molecular Genetics, 2010, Vol. 19, No. 3Figure 2. Expression of Hmgpi in preimplantation embryos and other tissues. (A) RT–PCR analysis of Hmgpi expression during preimplantation and postim-
plantation development (E7–E17). Three sets of 10 pooled embryos were collected from each stage (O: oocyte, F: fertilized egg, 2: 2-cell embryo, 4: 4-cell
embryo, 8: 8-cell embryo, M: morula, and B: blastocyst) and used for RT–PCR analysis. The predicted sizes of the PCR products of Hmgpi and Gapdh are
406 and 373 bp, respectively. No PCR products were detected in the no-RT negative control (4-cell embryo). (B) RT–PCR analysis of Hmgpi expression in
adult tissues, ES cells, EC cells and mesenchymal stem cells. mRNA was isolated from mouse tissues (H: heart, Bl: bladder, S: spleen, Lu: lung, Li: liver,
Mu: muscle, K: kidney, T: testis, ES: ES cells, EC: EC cells, and MSC: mesenchymal stem cells). No PCR products were detected in the no-RT negative
control (ES cells). (C) Real-time quantitative RT–PCR analysis of Hmgpi expression during preimplantation development. Fold differences in amounts of
Hmgpi mRNA from the same numbers of oocytes (O), fertilized eggs (F), 2-cell embryos (2), 4-cell embryos (4), 8-cell embryos (8), morulae (M) and blastocysts
(B) are shown after normalization to an internal reference gene (mouse H2afz). Values are means+SE from four separate experiments. (D) De novo (zygotic)
transcription of the Hmgpi gene. a-Amanitin studies revealed that Hmgpi is transcribed zygotically, but not maternally. Hmgpi expression was not observed
before the 2-cell stage and a-amanitin completely inhibited de novo transcription at the 2-cell stage (closed rhombus: control group, open square:
a-amanitin-treated group). The expression levels were normalized using H2afz as a reference gene. Values are means+SE from four separate experiments.
(E) Immunocytochemical analysis of HMGPI expression. MII oocytes and preimplantation embryos were immunostained with an anti-HMGPI antibody
(red) and an anti-Histone-H2B antibody as a positive control of nuclear staining (green). Nuclei are shown by DAPI staining (blue). HMGPI protein was detected
from 4-cell embryos to blastocysts. (F) Immunoblot analysis of HMGPI during preimplantation development. An amount of extracted protein corresponding to
100 oocytes or embryos was loaded per lane. Actin was used as a loading control. The representative result is shown from three independent experiments.
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investigate de novo (zygotic) transcription of the Hmgpi gene.
The supplementation of a-amanitin during in vitro culture
from the 1-cell stage signiﬁcantly reduced Hmgpi mRNA
expression in the 2-cell embryos at post-hCG 43 and 53 h
(early and late 2-cell stage, respectively) (Fig. 2D), implying
that Hmgpi is transcribed zygotically during the major burst
of ZGA, but not maternally.
To study the temporal and spatial expression pattern of the
Hmgpi-encoded protein (HMGPI), we raised a polyclonal anti-
body against Hmgpi peptides. Western blot analysis of extracts
from the mouse blastocysts showed only a single band corre-
sponding to 46 kDa detected by the anti-HMGPI antibody. In
addition, preincubation with the HMGPI peptide antigen abol-
ished detection of the HMGPI protein, while preincubation
with a control peptide had no effect on the immunodetection
(Supplementary Material, Fig. S1). Although Hmgpi transcrip-
tion started at the 2-cell stage, peaked at the 4-cell stage and
then gradually decreased until the blastocyst stage (Fig. 2C),
immunostaining and immunoblotting analysis revealed
HMGPI expression from the 4-cell stage until the blastocyst
stage, indicating a delayed expression pattern of HMGPI com-
pared with that of the Hmgpi transcript. It was also notable that
both ICM cells and trophectodermal cells retained HMGPI
expression in blastocysts.
On the other hand, immunostaining for HMGPI in preim-
plantation embryos showed a unique subcellular localization
pattern. Although a putative nuclear protein due to its role
Figure 3. Localization of HMGPI in preimplantation embryos. (A) Nuclear translocation of HMGPI protein at the blastocyst stage. HMGPI was mainly detected
in the cytoplasm of preimplantation embryos (from 4-cell embryos to morulae), but in the nuclei of blastocysts. Nuclei are shown by immunostaining with an
anti-Histone-H2B antibody (green) and DAPI staining (blue). (B) Confocal microscopy images of blastocyst outgrowth and ES cells stained with antibodies to
Hmgpi and Oct4, and with DAPI. Scale bar ¼ 50 mM. (C) Western blotting analysis of HMGPI in cytoplasmic (Cy) and nuclear (Nu) fractions of ES cells. Lamin
A/C and tubulin were used as markers of the nuclear and cytoplasmic fractions, respectively.
484 Human Molecular Genetics, 2010, Vol. 19, No. 3Figure 4. Loss-of-function study by siRNA technology. (A) Transcript levels of Hmgpi in embryos injected with control siRNA (siControl) and Hmgpi siRNA
(siHmgpi) by real-time quantitative RT–PCR analysis. The expression levels were normalized using H2afz as a reference gene. Values are means+SE for four
separate experiments. (B) Laser scanning confocal microscopy images of HMGPI protein expression in a 4-cell embryo, 8-cell embryo, morula and blastocyst
after injection with siControl or siHmgpi (red, HMGPI; blue, chromatin). (C and D) Immunoblot analysis of HMGPI expression at the blastocyst stage in
siControl-injected and siHmgpi-injected embryos. The relative amount of HMGPI (46 kDa) was determined at the blastocyst stage (left: siControl-injected
embryos, right: siHmgpi-injected embryos). The expression levels were normalized using actin expression (42 kDa) as a reference. Values are means+SE
from three separate experiments.
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cytoplasm without any evidence of a nuclear localization
from the 4-cell to the morula stage, suggesting a role other
than transcriptional regulation (Fig. 2E). In contrast, HMGPI
was localized to the nuclei rather than to the cytoplasm of
blastocysts (Figs 2E and 3A). During blastocyst outgrowth,
HMGPI was expressed in the nuclear region of most outgrow-
ing cells, with scant amounts detected in the cytoplasm
(Fig. 3B). Interestingly, Oct4-positive cells derived from the
ICM showed particularly strong positive staining for HMGPI
in the nucleus, suggesting a speciﬁc role as a nuclear protein
in ES cells (Fig. 3B). On more closely examining HMGPI in
ES cells, we found that almost all the Oct4-positive undiffer-
entiated ES cells in a colony also expressed HMGPI (Fig. 3B),
and immunoblotting conﬁrmed HMGPI expression in both
nuclear and cytoplasmic fractions of ES cells (Fig. 3C).
Effect of siRNA on Hmgpi mRNA level and protein
synthesis
To investigate a role of Hmgpi in early embryonic develop-
ment, we knocked down Hmgpi expression in mouse preim-
plantation embryos. We employed an oligonucleotide-based
siRNA (denoted here siHmgpi and obtained from PE
Applied Biosystems, Foster City, CA, USA). Zygotes injected
with Hmgpi siRNAs (siHmgpi) or control siRNA (siControl)
and non-injected zygotes as negative controls were cultured.
Hmgpi expression was severely suppressed in the
siHmgpi-injected embryos, and signiﬁcantly lower than
those in the siControl-injected or non-injected embryos
(Fig. 4A). The siControl-injected embryos did not show any
difference from the non-injected embryos in Hmgpi expression
(data not shown). In addition, immunoﬂuorescent staining
clearly demonstrated that the siRNA injection reduced
HMGPI protein expression in an individual preimplantation
embryo (Fig. 4B). In the same set of experiments, the
HMGPI levels were also assayed by western blotting
(Figs 4C and 4D). HMGPI expression was signiﬁcantly
reduced in siHmgpi-injected blastocysts (0.89+0.10) com-
pared with that in negative controls (0.28+0.08; P , 0.05).
Furthermore, we conﬁrmed that siHmgpi had no inﬂuence
on the expression of other genes with sequence similarities
to Hmgpi, namely Ubtf, Hmgb1, Hmgb2 and Hmgb3. Although
Ubtf, Hmgb1, Hmgb2 and Hmgb3 were all expressed in control
preimplantation embryos, the siHmgpi construct used in this
study did not affect the expression of these genes in the
siHmgpi-injected embryos (Supplementary Material,
Fig. S2). On the other hand, it has been demonstrated that
loss-of-function of these genes produces no distinct pheno-
types at the pre- and peri-implantation stages (21).
Effect of Hmgpi siRNA on preimplantation development
To study the function of Hmgpi during preimplantation devel-
opment, siHmgpi-injected or siControl-injected zygotes were
cultured in vitro until the blastocyst stage. The embryos
injected with siHmgpi at 21–23 h after hCG administration
often failed to become blastocysts at 3.5 days postcoitum
(dpc) (Fig. 5A). In addition, the reduction in Hmgpi expression
signiﬁcantly suppressed preimplantation development,
whereby 68.9+1.3% of siHmgpi-injected embryos became
blastocysts, while 94.1+1.3% of siControl-injected
embryos reached the blastocyst stage (Supplementary
Material, Fig. S3; P , 0.0001). Most of the siHmgpi-injected
embryos that failed to become blastocysts showed develop-
mental arrest after the morula stage and did not appear to
form blastocoels, suggesting impairment of trophectodermal
development (Supplementary Material, Fig. S3). To analyze
the phenotype of siHmgpi-injected embryos further, we per-
formed immunoﬂuorescence staining of lineage-speciﬁc
markers such as Cdx2, Nanog and Oct4 at the blastocyst
stage. Although siHmgpi-injected embryos that reached the
blastocyst stage appeared morphologically intact, the
expression of lineage-speciﬁc markers was reduced
(Fig. 5B). Cdx2, which is required for implantation and extra-
embryonic development, was particularly and markedly down-
regulated in trophectodermal cells, while Nanog and Oct4
Figure 5. Function of Hmgpi in preimplantation development. (A) A pair of
representative photos showing the development of embryos injected with
Hmgpi siRNA (siHmgpi) and Control siRNA (siControl). The
siHmgpi-injected embryos arrested at the morula stage are indicated by
arrows. Scale bar ¼ 100 mM. (B) For Nanog, Oct4 and Cdx2 immunostaining,
all blastocysts in the siHmgpi-injected and siControl-injected groups were pro-
cessed simultaneously. The laser power was adjusted so that the signal inten-
sity was below saturation for the developmental stage that displayed the
highest intensity and all subsequent images were scanned at that laser
power. This allowed us to compare signal intensities for Nanog, Oct4 and
Cdx2 expression between the siHmgpi-injected and siControl-injected
embryos (Supplementary Material, Table S2).
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siHmgpi-injected embryos (Fig. 5B and Supplementary
Material, Table S2). Thus, Hmgpi is essential for the earliest
embryonic development; both ICM and trophectodermal
development.
Effect of Hmgpi siRNA on in vivo and in vitro
peri-implantation development
To investigate the role of Hmgpi in proliferation of the ICM
and trophectodermal cells, siHmgpi-injected and siControl-
injected embryos were further cultured in vitro from the
blastocyst stage, and attachment and outgrowth of each
embryo on gelatin-coated culture plates was examined.
HMGPI expression in siHmgpi-injected embryos was signiﬁ-
cantly reduced, and immunostaining showed that many colo-
nies of ICM cells in the embryos collapsed during outgrowth
culture (Fig. 6A and B). Although the vast majority of ICMs
from siControl-injected embryos showed successful attach-
ment (80.3+4.9%) and vigorous outgrowth (96.2+2.7%),
those from siHmgpi-injected embryos failed to proliferate or
produced only a residual mass (19.3+3.8%) despite success-
fully attaching (79.0+2.8%) (Fig. 6C; attachment ns; out-
growth, P , 0.001). These results implied that Hmgpi is
essential for proliferation of ICM and trophectodermal cells
in peri-implantation development, and for derivation of ES
cells.
We then investigated cell proliferation and apoptosis during
blastocyst outgrowth. Comparable incorporation of BrdU in
blastocyst outgrowths of siHmgpi-injected embryos was less
than that of siControl-injected embryos. Proliferation was sig-
niﬁcantly reduced in ICM-derived cells and dramatically sup-
pressed in trophoblast cells (Fig. 6D). Embryonic ﬁbroblasts
were used as a feeder layer in this study and could support
ICM cells, thus proliferation should have proceeded regardless
of trophectodermal cell support. Therefore, the collapsed
ICM-derived colonies in the current experiment were not a
secondary effect of reduced proliferation in trophoblast cells,
but a direct effect of the siHmgpi-induced decrease in ICM
proliferation. Apoptosis was not detected in any cells during
blastocyst outgrowth of siHmgpi-injected embryos, based on
the absence of active caspase3 (Fig. 6E). Taken together,
these ﬁndings show that Hmgpi is indispensable for prolifer-
ation of the ICM and trophectodermal cells in peri-
implantation development and for the generation of ES cells.
Finally, we tested whether the experimental blastocysts
could develop in vivo by transferring siHmgpi-injected and
siControl-injected blastocysts into the uterus of pseudopreg-
nant mice. Only 45.8+9.7 and 24.7+3.3% of blastocysts
injected with siHmgpi implanted and developed, respectively,
whereas most of the siControl-injected embryos showed
successful implantation and ongoing development (76.5+
4.0 and 66.6+3.3%, respectively) (Fig. 6F; implanted, P ,
0.05; ongoing pregnancy, P , 0.0001). These results con-
ﬁrmed a role for Hmgpi in peri-implantation embryonic devel-
opment.
DISCUSSION
We previously analyzed the dynamics of global gene
expression changes during mouse preimplantation develop-
ment (3). Understanding these preimplantation stages is
important for both reproductive and stem cell biology. Many
genes showing wave-like activation patterns (e.g. ZGA and
MGA) during preimplantation were identiﬁed, and any or all
of these may contribute to the complex gene regulatory net-
works. Hmgpi, one of the few novel preimplantation-speciﬁc
genes, is involved in early development, implantation and
ES cell derivation.
Structure-based prediction of Hmgpi function
Structural information about a protein sometimes hints at func-
tional mechanisms, which remain unknown for Hmgpi’s clear
role in early embryonic development. The HMG family pro-
teins are abundant nuclear proteins that bind to DNA in a
non-sequence-speciﬁc manner, inﬂuence chromatin structure
and enhance the accessibility of binding sites to regulatory
factors (17). Based on the number and the type of HMG
domains, Hmgpi is relevant to the HMGB subfamily, charac-
terized by containing two HMG-box domains (‘HMG-box’
or ‘HMG-UBF_HMG-box’), rather than either the HMGA or
HMGN subgroups. Hmgpi is also known as Ubtﬂ1 in the
NCBI gene database, based on sequence similarity to Ubtf,a
well-known ZGA gene (3,22). Ubtf, encoding a SANT
domain and six HMG-box domains, functions exclusively in
RNA polymerase I (Pol I) transcription (23) and acts
through its multiple HMG boxes to induce looping of DNA,
which creates a nucleosome-like structure to modulate tran-
Figure 6. Function of Hmgpi in peri-implantation development. (A) Blastocyst outgrowth and alkaline phosphatase (AP) activity in the siHmgpi-injected and
siControl-injected embryos, carried out according to a standard procedure (42). Representative images of phase-contrast microscopy for blastocyst outgrowth and
ﬂuorescent immunocytochemistry for AP are shown. Scale bar ¼ 100 mM. (B) Confocal microscopy images of blastocyst outgrowth for the siHmgpi-injected
and siControl-injected embryos, stained with antibodies to Hmgpi and Oct4. Nuclei are shown by DAPI staining. Scale bar ¼ 100 mM. (C) Successful rate of
blastocyst outgrowth for siHmgpi-injected and siControl-injected embryos. Successful outgrowth in this assay was indicated by the presence of proliferating cells
after 6 days in culture. The experiment was repeated four times. (D) BrdU incorporation assay for blastocyst outgrowth of the siHmgpi-injected and
siControl-injected embryos. Cell proliferation was determined by BrdU incorporation (ICM: arrowhead, trophectodermal cells: arrow). The trophectodermal
component contained few cells and BrdU incorporation was conﬁned to the ICM core; however, cell proliferation was reduced in the blastocyst outgrowth
of siHmgpi-injected embryos compared with that of the siControl-injected embryos. Nuclei are shown by DAPI staining. Scale bar ¼ 100 mM. (E) Immunocyto-
chemistry with an anti-caspase3 antibody in blastocyst outgrowth of the siHmgpi-injected and siControl-injected embryos. Apoptotic cells were not apparent in
the blastocyst outgrowth of either injected embryo. Nuclei are shown by DAPI staining. Scale bar ¼ 100 mM. (F) Successful rate of siHmgpi-injected and
siControl-injected embryo transfer. We transferred 3.5 dpc blastocysts into the uteri of 2.5 dpc pseudopregnant ICR female mice. The pregnant ICR mice
were sacriﬁced on day 12.5 of gestation and the total numbers of implantation sites and of live and dead embryos/fetuses were counted. The experiment
was repeated four times.
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Pol I (24,25). Because the association of UBTF with rRNA
genes in vivo is not restricted to the promoter and extends
across the entire transcribed portion, UBTF promotes the for-
mation of nucleolar organizer regions, indicative of ‘open’
chromatin (26). Based on the sequence similarity between
UBTF and HMGPI, HMGPI might also bind to DNA in a non-
speciﬁc manner, and modulate chromatin during peri-
implantation when dynamic chromatin change is essential.
Alternatively, HMGPI may act as a cytokine during preim-
plantation development in a similar manner to HMGB1.
HMGB proteins are found primarily in the cell nucleus, but
also to varying extents in the cytosol (27,28), and have been
suggested to shuttle between compartments (17). HMGB1 is
indeed passively released from nuclei upon cell death and
actively secreted as a cytokine (29), and the addition of recom-
binant HMGB1 into culture medium enhances in vitro devel-
opment of mouse zygotes to the blastocyst stage in the
absence of BSA supplementation (30). Although HMGPI
failed to be detected in culture media after in vitro culture
of preimplantation embryos or ES cells in this study (data
not shown), two different modes of Hmgpi action, chromatin
modulator and secreted mediator, should be taken into con-
sideration as discussed later.
Role of Hmgpi during peri-implantation
The HMGPI protein was ﬁrst detected in 4-cell embryos and
then abundantly expressed in 8-cell embryos, morulae, ICM,
trophectoderm and ES cells. Although Hmgpi transcription
peaked at the 4-cell stage, the most dramatic siRNA effect
appeared at the blastocyst and subsequent stages. This discre-
pancy between temporal expression and phenotype is attribu-
ted to three possible mechanisms. First, protein expression is
generally delayed from transcription, indicated here by the
Hmgpi transcripts and HMGPI protein expression peaking at
the 4-cell stage and blastocyst stage, respectively. Similarly,
Stella (31) and Pms2 (32) are maternal-effect genes, but do
not cause developmental loss until later preimplantation
stages. A second possibility is the incompleteness of siRNA
knockdown. One limitation of such knockdown experiments
is the potential variability in levels of silencing of a target
gene, which could in turn underlie the observed phenotypic
variability in the present study. Embryos with complete sup-
pression of Hmgpi may exhibit developmental arrest at
earlier stages (e.g. at the morula stage), while those with
less suppression may not display a phenotype until the later
stages (e.g. at the implantation stage). Ideally, the suppression
level of each embryo could be experimentally analyzed to cor-
relate with the phenotype. The third possibility is spatial trans-
location of HMGPI protein in the blastocyst cells. The HMGPI
expression pattern indicated differential spatial requirements
during early embryogenesis, supported by the apparent
ability of HMGPI to shuttle between the nucleus and the cyto-
plasm; the cytoplasmic HMGPI observed from the 4-cell to
morula stages and the nuclear HMGPI in blastocysts and ES
cells could have different functions. A bipartite nuclear local-
ization signal (NLS) peptide (FKKEKEDFQKKMRQFKK)
similar to NLS of HMGN2/HMG-17 (33) is also present in
the HMGPI sequence. Thus, the nuclear HMGPI in blastocysts
and ES cells might exert a critical transcriptional role to regu-
late gene expression essential for peri-implantation develop-
ment. Indeed, the siHmgpi-induced knockdown of Hmgpi
expression downregulated Cdx2 in trophectodermal cells and
Oct4 and Nanog in ICM cells, with subsequently reduced pro-
liferation of trophectodermal cells and ICM-derived cells
during blastocyst outgrowth.
Genes indispensable for derivation of ES cells
Like Hmgpi, Zscan4 is another exclusively zygotic gene not
expressed at any other developmental stage (13). Zscan4 is a
putative transcription factor harboring a SCAN domain and
zinc ﬁnger domains, and transcribed not only in preimplanta-
tion embryos but also in ES cells (13). Reduction of Zscan4 by
RNA interference showed a phenotype similar to that induced
by Hmgpi knockdown: developmental deterioration at the pre-
implantation stages, especially cleavage pause at 2-cell stage,
and failure in blastocyst outgrowth, ES-cell derivation and
implantation. Thus, a preimplantation-speciﬁc gene expression
pattern could indicate a function in ES-cell derivation and/or
maintenance. Indeed, Hmgpi was also expressed in entire ES
colonies, whereas Zscan4 shows a peculiar mosaic expression
pattern in undifferentiated ES cell colonies. Furthermore, the
Hmgpi gene is highly expressed in ES cells, but not in EC
cells; Hmgpi is thus eligible as a putative ECAT (ES
cell-associated transcript), whose ESTs are overrepresented
in cDNA libraries from ES cells compared with those from
somatic tissues and other cell lines including EC cells (34).
It is also likely that Hmgpi is expressed in iPS cells, based
on in silico analyses of expression proﬁles [NCBI GEO data-
base, e.g. GSE10806 (35)]. Thus, Hmgpi is likely to have a
role in maintaining pluripotent cells, since the ECATs such
as Nanog, Eras and Gdf3 are required for pluripotency and
proliferation of ES cells (34,36,37). In the current study,
Hmgpi was indeed involved in blastocyst outgrowth of ICM
cells. On the other hand, several genes including ECAT
members have been implicated in trophectodermal develop-
ment as well as in early embryonic development. Like
Hmgpi that was expressed in both ICM cells and trophectoder-
mal cells, Dnmt3l/Ecat7 has a role in embryonic and extra-
embryonic tissues in early developmental stages. DNMT3L
is recruited by DNMT3A2 to chromatin (38) to function in
DNA methylation in ES cells, and defects in maternal
DNMT3L induce a differentiation defect in the extra-
embryonic tissue (39). The reduced CDX2 expression in
blastocysts and poor BrdU incorporation during blastocyst out-
growth following siHmgpi knockdown suggested the potential
involvement of Hmgpi in trophectodermal development.
In summary, Hmgpi is required early on in mammalian
development to generate healthy blastocysts that implant
successfully and produce ES cells. HMGPI translocates into
the nucleus from cytoplasm at the blastocyst stage, which is
importantly a turning point of early embryonic development
when DNA-methylation levels are at their lowest and implan-
tation takes place. The nuclear HMGPI in blastocysts and ES
cells is expected to act as a transcription factor to regulate
gene expression networks underlying the generation, self-
renewal and maintenance of pluripotent cells. Because E7
embryos have already stopped expressing Hmgpi, it is likely
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peri-implantation development. It will be valuable to identify
both cofactors that bind HMGPI and recognize speciﬁc DNA
sequences, as well as genes that are regulated by Hmgpi using
ES cells. A better understanding of the Hmgpi transcriptional
network will also improve culture methods for healthy blasto-
cysts and for generating, maintaining and differentiating ES
cells.
MATERIALS AND METHODS
Identiﬁcation of the mouse Hmgpi gene by in silico analysis
Preimplantation-speciﬁc genes were identiﬁed based on global
gene expression proﬁling of oocytes and preimplantation
embryos (3,40) and expressed sequence tag (EST) frequencies
in the Unigene database. SMART (19) was used for domain
prediction analysis. Orthologous relationships between HMG
family genes were identiﬁed from phylogenetic-tree amino
acid sequences determined by a sequence distance method
and the Neighbor Joining (NJ) algorithm (41) using Vector
NTI software (Invitrogen, Carlsbad, CA, USA).
Collection and manipulation of embryos
Six- to 8-week-old B6D2F1 mice were superovulated by
injecting 5 IU of pregnant-mare serum gonadotropin (PMS;
Calbiochem, La Jolla, CA, USA) followed by 5 IU of
human chorionic gonadotropin (HCG; Calbiochem) 48 h
later. The Institutional Review Board of the National Research
Institute for Child Health and Development, Japan granted
ethics approval for embryo collection from the mice. Unferti-
lized eggs were harvested 18 h after the HCG injection by a
standard published method (42), and the cumulus cells were
removed by incubation in M2 medium (EmbryoMax M-2
Powdered Mouse Embryo Culture Medium; Millipore,
Billerica, MA, USA) supplemented with 300 mg/ml hyaluroni-
dase (Sigma-Aldrich, St Louis, MO, USA). The eggs were
then thoroughly washed, selected for good morphology and
collected. Fertilized eggs were also harvested from mated
superovulated mice in the same way as unfertilized eggs and
embryos with two pronuclei (PN) were collected to synchro-
nize in vitro embryo development. Fertilized eggs were cul-
tured in synthetic oviductal medium enriched with potassium
(EmbryoMax KSOM Powdered Mouse Embryo Culture
Medium; Millipore) at 378C in an atmosphere of 95% air/
5% CO2. Cultured blastocysts were transferred into pseudo-
pregnant recipients as described previously (42). We trans-
ferred 3.5 dpc blastocysts into the uteri of 2.5 dpc
pseudopregnant ICR female mice. RNA interference exper-
iments were carried out by microinjecting ,10 pl (25 ng/ml)
of oligonucleotides (siHmgpi and siControl) into the
cytoplasm of zygotes. The optimal siRNAs were determined
by testing different concentrations (5, 10, 25 and 50 ng/ml)
of three siRNAs (PE Applied Biosystems, Foster City, CA,
USA), resuspended and diluted with the microinjection
buffer (Millipore). Their target sequences are listed in Sup-
plementary Material, Table S3. More than 10 independent
experiments were performed to study the effect of Hmgpi
knockdown on preimplantation development and implantation.
Culture of ES cells and blastocyst outgrowth
A mouse ES cell line (B6/129ter/sv line) was ﬁrst cultured for
two passages on gelatin-coated culture dishes in the presence
of leukemia inhibitory factor (LIF) to remove contaminating
feeder cells. Cells were then seeded on gelatin-coated 6-well
plates at a density of 1–2   10
5/well (1–2   10
4/cm
2) and
cultured for 3 days in complete ES medium: KnockOut
DMEM (Invitrogen) containing 15% KnockOut Serum Repla-
cement (KSR; Invitrogen), 2000 U/ml ESGRO (mLIF; Chemi-
con, Temecula, CA, USA), 0.1 mM non-essential amino acids,
2m M GlutaMax (Invitrogen), 0.1 mM beta-mercaptoethanol
(2-ME; Invitrogen) and penicillin/streptomycin (50 U/50 mg/
ml; Invitrogen). Blastocyst outgrowth experiments were
carried out according to a standard procedure (42). In brief,
zona pellucidae of blastocysts at 3.5 dpc were removed
using acidic Tyrode’s solution (Sigma). The blastocysts were
cultured individually in the ES medium on gelatinized
chamber slides at 378C in an atmosphere of 5% CO2. The cul-
tured cells were examined and photographed daily. Alkaline
phosphatase activity was measured using a speciﬁc detection
kit (Vector Laboratories, CA, USA) after 6 days in culture.
Four independent experiments were performed.
Immunostaining of oocytes and preimplantation embryos
Samples were ﬁxed in 4% paraformaldehyde (Wako Pure
Chemical, Osaka, Japan) with 0.1% glutaraldehyde (Wako)
in phosphate-buffered saline (PBS) for 10 min at room temp-
erature (RT), and then permeabilized with 0.5% Triton X-100
(Sigma) in PBS for 30 min. Immunocytochemical staining was
performed by incubating the ﬁxed samples with primary
antibodies for 60 min, followed by secondary antibodies for
60 min. A polyclonal antibody to mouse HMGPI was raised
in rabbits against three synthesized peptides designed accord-
ing to sequence speciﬁcity, homology between mouse and
human HMGPI, antigenicity, hydrophilicity and synthetic
suitability [(i) CIQGHHDGAQSSRQDFTD, (ii) CMSMSGG
RSSKFGRTEQS, (iii) ESPRTVSSDMKFQGC; Medical &
Biological Laboratories Co, Nagoya, Japan). The anti-HMPGI
was used at 1:300 dilution, followed by Alexa Fluor 546 goat
anti-rabbit IgG (Molecular Probes, Invitrogen) as the second-
ary antibody. The anti-Histone H2B antibody (Medical &
Biological Laboratories Co, Nagoya, Japan) was used at
1:300 dilution as positive control of nuclear staining, followed
by Alexa Fluor 488 goat anti-mouse IgG (Molecular Probes,
Invitrogen) as the secondary antibody. Blastocysts were
immunostained using a monoclonal anti-Oct4 antibody
(mouse IgG2b isotype, 200 mg/ml; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), rabbit polyclonal anti-Nanog antibody
(ReproCELL, Tokyo, Japan), mouse monoclonal anti-Cdx2
antibody (CELL MARQUE, Rocklin, CA, USA), mouse
monoclonal anti-BrdU antibody (Santa Cruz) and rabbit
monoclonal anti-active caspase 3 (Abcam) antibody, all
diluted at 1:50–300. The appropriate secondary antibodies
(IgG) were diluted at 1:300 and supplied by Molecular
Probes/Invitrogen: goat anti-rabbit IgG conjugated with
Alexa Fluor 546 and goat anti-mouse IgG(H þ L) conjugated
with Alexa Fluor 488. The cellular DNA (nuclei) was stained
with 40,6-diamidino-2-phenylindole (DAPI; Wako; diluted
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laser confocal microscopy (LSM510, Zeiss). For HMGPI
immunostaining, all samples were processed simultaneously.
The laser power was adjusted so that the signal intensity
was below saturation for the developmental stage that dis-
played the highest intensity and all subsequent images were
scanned at that laser power. This allowed us to compare
signal intensities for HMGPI expression at different develop-
mental stages. The other molecules in blastocysts and out-
growth were viewed and imaged as for the HMGPI expression.
Immunocytochemistry of blastocyst outgrowths
and ES cells
Cultured ES cells and blastocyst outgrowths were ﬁxed with
4% paraformaldehyde for 10 min at 48C, treated with 0.1%
Triton X-100 (Sigma) in PBS for 15 min at RT, and then incu-
bated for 30 min at RT in protein-blocking solution consisting
of PBS supplemented with 5% normal goat serum (Dako,
Glostrup, Denmark). The samples were then incubated over-
night with the primary antibodies to OCT4, HMGPI, BrdU
or active caspase 3 in PBS at 48C. The cells were then exten-
sively washed in PBS and incubated at RT with Alexa Fluor
488 goat anti-mouse IgG1 (anti-OCT4 and anti-BrdU anti-
bodies, diluted 1:300; Molecular Probes) or Alexa Fluor 546
goat anti-rabbit IgG(H þ L) (anti-HMGPI and anti-caspase 3
antibodies, diluted 1:300), and nuclei were counterstained
with DAPI for 30 min. To prevent fading, cells were then
mounted in Dako ﬂuorescent mounting medium (Dako).
Incorporation of bromodeoxyuridine (BrdU)
E3.5 blastocysts and blastocyst outgrowths were cultured for
16 h in KSOM and ES medium, respectively, supplemented
with 10 mM BrdU (Sigma). Samples were then ﬁxed in 4%
paraformaldehyde for 20 min, washed in PBS and then
treated with 0.5 M HCl for 30 min.
RNA extraction and real-time quantitative reverse
transcriptase (qRT)–PCR
Embryos for qRT–PCR analysis were collected at 18 h
post-hCG and cultured as described above. They were har-
vested at 0.5, 1.25, 1.75, 2.25, 2.75 and 3.75 dpc to obtain fer-
tilized eggs 2-cell, 4-cell, 8-cell, morula and blastocyst
embryos, respectively. Three subsets of 10 and 50 synchro-
nized and intact embryos were transferred in PBS sup-
plemented with 3 mg/ml polyvinylpyrrolidone (PVP) and
stored in liquid nitrogen. Total RNA from 10 and 50
embryos was extracted using the PicoPure RNA Isolation
Kit (Arcturus, La Jolla, CA, USA). The reverse transcription
reaction, primed with polyA primer, was performed using
Superscript III reverse transcriptase (Invitrogen) following
the manufacturer’s instructions. Total RNA isolated was
reverse transcribed in a 20 ml volume. The resulting cDNA
was quantiﬁed by qRT–PCR analysis using the SYBR
Green Realtime PCR Master Mix (Toyobo, Osaka, Japan)
and ABI Prism 7700 Sequence Detection System (PE
Applied Biosystems) as described previously (43). An
amount of cDNA equivalent to 1/2 an embryo was used for
each real-time PCR reaction with a minimum of three repli-
cates, with no-RT and no-template controls for each gene.
Data were normalized against H2afz by the DDCt method
(44). PCR primers for the genes of Hmgpi, H2afz and
Gapdh were listed in Supplementary Material, Table S4. Cal-
culations were automatically performed by ABI software
(Applied BioSystems). For alpha-amanitin studies, fertilized
eggs were ﬁrst harvested at 18 h post-hCG, instead of eggs
already advanced to the two-pronucleus stage. After 3 h of
incubation, eggs that carried both male and female pronuclei
were selected at 21 h post-hCG and randomly assigned to
two experimental groups: with and without addition of
alpha-amanitin to the culture medium. The eggs were further
cultured in KSOM at 378C in an atmosphere of 5% CO2
until the speciﬁed time point (32, 43 and 54 h post-hCG).
Embryos used for alpha-amanitin studies and RNA interfer-
ence experiments were subjected to qRT–PCR as described
for the normal preimplantation embryos.
Immunoblot analysis
Protein samples from embryos were solubilized in Sample
Buffer Solution without 2-ME (Nacalai Tesque, Kyoto,
Japan), resolved by NuPAGE Novex on Tris-acetate mini
gels (Invitrogen), and transferred to Immobilon-P transfer
membrane (Millipore). The membrane was soaked in protein
blocking solution (Blocking One solution, Nacalai) for
30 min at RT before an overnight incubation at 48C with
primary antibody, also diluted in blocking solution. The mem-
brane was then washed three times with TBST (Tris-buffered
saline with 0.1% Tween-20), incubated with a horseradish
peroxidase-conjugated secondary antibody (0.04 mg/ml)
directed against the primary antibody for 60 min, and
washed three times with TBST. The signal was detected by
enhanced chemiluminescence (SuperSignal West Dura
Extended Duration Substrate, Thermoscientiﬁc, Rockford,
IL, USA) following the manufacturer’s recommendations.
The intensity of the band was quantiﬁed using NIH Image J
software. Brieﬂy, the signal was outlined and the mean inten-
sity and background ﬂuorescence were measured. The speciﬁc
signal was calculated by dividing the band intensities for
HMGPI by those for actin.
Statistical analysis
Differences between groups were evaluated statistically using
Student’s t-test or ANOVA, with P-values , 0.05 considered
signiﬁcant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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